FDA’s Warning Letters Send a Clear Signal: Unapproved Drugs Are in the Crosshairs

CDER’s Office of Unapproved Drugs and Labeling Compliance (“OFDL”) has taken the lead in addressing high-priority enforcement areas involving unapproved new drugs. Over the course of 2026, OFDL has issued warning letters concerning violations of the Federal Food, Drug, and Cosmetic Act’s (“FD&C Act”) prohibition on introducing unapproved new drugs into interstate commerce, focusing on […]